Doorgaan naar hoofdcontent

Human medicines European public assessment report (EPAR): Tysabri, natalizumab, Multiple Sclerosis, Date of authorisa...

 

 
 
Human medicines European public assessment report (EPAR): Tysabri, natalizumab, Multiple Sclerosis, Date of authorisation: 27/06/2006, Revision: 34, Status: Authorised
Human medicines European public assessment report (EPAR): Tysabri, natalizumab, Multiple Sclerosis, Date of authorisation: 27/06/2006, Revision: 34, Status: Authorised



 
 
Human medicines European public assessment report (EPAR): Pregabalin Pfizer, pregabalin, Anxiety Disorders,Epilepsy, Date of authorisation: 10/04/2014, Revision: 22, Status: Authorised
Human medicines European public assessment report (EPAR): Pregabalin Pfizer, pregabalin, Anxiety Disorders,Epilepsy, Date of authorisation: 10/04/2014, Revision: 22, Status: Authorised



 
 
Human medicines European public assessment report (EPAR): Opdivo, nivolumab, Melanoma,Hodgkin Disease,Carcinoma, Renal Cell,Carcinoma, Non-Small-Cell Lung,Squamous Cell Carcinoma of Head and Neck,Carcinoma, Transitional Cell,Urologic Neoplasms, Date of a
Human medicines European public assessment report (EPAR): Opdivo, nivolumab, Melanoma,Hodgkin Disease,Carcinoma, Renal Cell,Carcinoma, Non-Small-Cell Lung,Squamous Cell Carcinoma of Head and Neck,Carcinoma, Transitional Cell,Urologic Neoplasms, Date of authorisation: 19/06/2015, Revision: 37, Status: Authorised


Actueel zorgnieuws in jouw mailbox ontvangen?
Direct het hele artikel lezen? Meld je aan voor de nieuwsbrief.